tirzepatide phase 1 for type diabetes and obesity Four Target Combination Therapy: GLP-1-GIP-GCG-IGF-1

14.4 MOUNJARO Use in Combination with Basal Insulin with or without Metformin in Adult Patients with Type 2 Diabetes Mellitus SURPASS-5 (NCT04039503) was a 40-week double-blind trial that randomized 475 adult patients with type 2 diabetes mellitus with inadequate glycemic control on insulin glargine 100 units/mL, with or without metformin, to subcutaneous MOUNJARO 5 mg, MOUNJARO 10 mg, MOUNJARO 15 mg once weekly, or placebo

Best fiber sources that do not aggravate side effects Soluble fiber dissolves in water and forms a gel

Cravings, particularly for high-calorie and high-sugar foods, often diminish noticeably

Tirzepatide activates two: GLP-1, which slows digestion and helps regulate appetite, and GIP, which influences how your body responds to insulin and stores energy